Longeveron Inc. (NASDAQ:LGVN) Short Interest Update

Longeveron Inc. (NASDAQ:LGVN) was the recipient of a significant growth in short interest in the month of June. As of June 15th, there was short interest totalling 2,970,000 shares, a growth of 5,290.2% from the May 31st total of 55,100 shares. Approximately 67.4% of the shares of the stock are short sold. Based on an average trading volume of 8,250,000 shares, the short-interest ratio is presently 0.4 days.

Insider Buying and Selling at Longeveron

In related news, insider Joshua Hare purchased 106,383 shares of Longeveron stock in a transaction that occurred on Wednesday, April 10th. The shares were acquired at an average price of $2.35 per share, for a total transaction of $250,000.05. Following the transaction, the insider now directly owns 590,727 shares in the company, valued at $1,388,208.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Rock Soffer purchased 31,915 shares of Longeveron stock in a transaction dated Thursday, April 11th. The shares were acquired at an average cost of $2.35 per share, for a total transaction of $75,000.25. Following the transaction, the director now directly owns 208,534 shares of the company’s stock, valued at $490,054.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Joshua Hare acquired 106,383 shares of the firm’s stock in a transaction that occurred on Wednesday, April 10th. The shares were bought at an average cost of $2.35 per share, with a total value of $250,000.05. Following the completion of the purchase, the insider now owns 590,727 shares of the company’s stock, valued at $1,388,208.45. The disclosure for this purchase can be found here. Insiders have purchased 148,936 shares of company stock worth $350,000 over the last three months. Company insiders own 19.12% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Longeveron stock. Armistice Capital LLC acquired a new position in shares of Longeveron Inc. (NASDAQ:LGVN) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,836,000 shares of the company’s stock, valued at approximately $2,497,000. Armistice Capital LLC owned approximately 7.31% of Longeveron as of its most recent SEC filing. 10.01% of the stock is owned by hedge funds and other institutional investors.

Longeveron Trading Down 4.2 %

Shares of Longeveron stock traded down $0.07 during trading on Friday, reaching $1.61. The stock had a trading volume of 751,568 shares, compared to its average volume of 19,945,396. The company has a market capitalization of $10.22 million, a price-to-earnings ratio of -0.17 and a beta of 0.33. The stock has a fifty day moving average price of $1.57 and a two-hundred day moving average price of $5.48. Longeveron has a 52 week low of $0.77 and a 52 week high of $37.50.

Longeveron (NASDAQ:LGVN) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($1.61) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.01) by $0.40. Longeveron had a negative return on equity of 300.96% and a negative net margin of 2,129.24%. The firm had revenue of $0.55 million during the quarter, compared to the consensus estimate of $0.12 million. During the same quarter in the prior year, the firm posted ($2.20) EPS. On average, equities analysts forecast that Longeveron will post -3.87 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Longeveron in a research report on Friday, May 17th.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.